Clinical Trial Update: PAS-004 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of PAS-004 in patients with advanced solid tumors is currently recruiting, with eligibility including tumors bearing RAS, NF1, or RAF mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PAS-004

Snippet

Sponsor: Pasithea Therapeutics Corp. | Conditions: RAS Mutation, NF1 Mutation | Phase 1 | Status: RECRUITING